Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACCO trial of inhaled ciclesonide for mild or asymptomatic COVID-19
jRCTs031190269Phase 2Completed
- Sponsor
- Health and Labour Sciences Research Grants
- Start
- Apr 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ciclesonide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Health and Labour Sciences Research Grants. Primary endpoint: Pneumonia incidence on day 8 of ciclesonide inhalation. Started Apr 2020; status: completed.
02
Drugs
ciclesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031190269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190269.